ArticleFrontiers in pharmacology2025
Pre-prescription review system improves prescription safety, efficiency, and cost-effectiveness in pediatric outpatients: a western China study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dynamic evaluation and continuous improvement model of pharmaceutical administration based on DPSIR-TOPSIS.BMC health services research · 2026Article
- Rational Corticosteroid Use: An Evidence-Based Narrative Review of Steroid Stewardship to Enhance Patient Safety Across Healthcare Settings.Drug, healthcare and patient safety · 2026Review
- Construction and refined management of a pre-prescription review system: a real-world study in a tertiary hospital.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The study's objective is to investigate the prescription rationality rate, time efficiency, and estimated economic benefits of a pre-prescription review system (PPRS) in pediatric outpatients in a 5-year retrospective study in western China. Method: This retrospective before-after study compared data from two phases: pre-intervention phase (2019: PPRS not yet implemented), and post-intervention phase (2020-2023: PPRS fully operational). The study evaluated three key endpoints: primary endpoint was the prescription rationality rate; the secondary endpoints were time efficiency (interval from prescription to drug dispensing) and suggested economic benefits (estimated benefit-cost ratio). Descriptive analyses were conducted to investigate the prescription rationality rate before and after PPRS implementation. The time interval from prescription to drug dispensing was analyzed from 2019 to 2023 using one-way ANOVA. Suggested economic benefit was evaluated under the healthcare system perspective with estimated benefit-cost ratio. Results: The PPRS implementation was correlated with an increase in the rational prescription rate in outpatient department from 91.19% in 2019 to 98.79% in 2023 and a reduction in time interval from prescription to dispensing from 19.59 min in 2019 to 16.33 min in 2020 ( Conclusion: The implementation of PPRS was associated with enhanced prescription rationality and time efficiency in pediatric outpatient settings while indicating potential economic benefits. This PPRS is worthy of popularization but needs to be validated across diverse populations and institutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.